New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Abstract

Summary The International Prognostic Index (IPI) is the most widely used score for non‐Hodgkin lymphoma but lacks the ability to identify a high‐risk population in diffuse large B‐cell lymphoma (DLBCL). Low absolute lymphocyte count and high monocytes have proved to be unfavourable factors. Red‐cell distribution width (RDW) has been associated with inflammation and beta‐2 microglobulin (B2M) with tumour load. The retrospective study included 992 patients with DLBCL treated with R‐CHOP. In the multivariate analysis, age, Eastern Cooperative Oncology Group performance status (ECOG‐PS), stage, bulky mass, B2M, RDW, and lymphocyte/monocyte ratio (LMR) were independently related to progression‐free survival (PFS). A new prognosis score was generated with these variables including age categorized into three groups (0, 1, 2 points); ECOG ≥ 3–4 with two; stage III/IV, bulky mass, high B2M, LMR < 2·25 and RDW > 0·96 with one each; for a maximum of 9. This score could improve the discrimination of a very high‐risk subgroup with five‐year PFS and overall survival (OS) of 19% and 24% versus 45% and 59% of R (revised)‐IPI respectively. This score also showed greater predictive ability than IPI. A new score is presented including complete blood cell count variables and B2M, which are readily available in real‐life practice without additional tests. Compared to R‐IPI, it shows a more precise high‐risk assessment and risk discrimination for both PFS and OS.

The Clinical Implication of Dynamic Hematological Parameters in COVID-19: A Retrospective Study in Chongqing, China

“…High monocyte count and low lymphocyte count indicate increased mortality and declined prognosis in a variety of disorders. 21 It's reported that LMR is a highly sensitive analyzing item used for diagnosis of diabetes, 22 large B-cell lymphoma, 23 cardiovascular diseases, 21 , 24 , 25 and COVID-19, 26 and so on.…”

<p>Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis</p>

“…33 In general, pathological examination of suspicious tissue obtained from a biopsy or resection is considered as the gold standard procedure for definitive diagnosis when the intracranial lesion is uncertain, whereas CT and MRI are the important supplemental diagnostic approaches for assistance of diagnosis, tumor staging, and evaluation of therapeutic efficacy. 9 However, both the neuroimaging tests and pathological examination are expensive with limited sensitivity, even at risk of hemorrhage and neurologic impairment, which have greatly limited their application for the clinical differential diagnosis. 10 Thus, there is an urgent need for the low cost, easily obtained, and minimally invasive markers with improved diagnostic sensitivity and specificity for patients with HGG and sBM.…”

“…8 Recently, the clinical application values of serum β2-microglobulin (β2-m) in predicting prognosis and monitoring of therapeutic efficacy has been rapidly highlighted. 9 Several studies have shown an increased level of β2-m in solid tumors, including lung cancer and gastrointestinal cancer. [10][11][12] However, the expression of β2-m in HGG and sBM remains unknown.…”

Lactate dehydrogenase, Beta-2 Microglobulin Levels and CD4/CD8 Lymphocyte Ratio in Patients with Mycosis Fungoides in Stage 1A

“…Beta-2 microglobulin is a small polypeptide light chain that forms part of the major histocompatibility complex class I antigens. As white-blood-cell membrane turnover is the primary source of serum beta-2 microglobulin, elevated serum betamicroglobulin levels have been associated with lymphoid malignancies with significant tumour burden, high rates of cellular turnover and more invasive potential [4].…”